Wall Street is being nicer on earnings as vaccine makers, fintech reports near

With a downcast earnings season passing the halfway mark, results from pharma and fintech companies will dominate the week ahead. Read More...

Motley Fool

Why Shares of Vaxcyte Rose 110.7% This Week

Shares of Vaxcyte (NASDAQ: PCVX), a clinical-stage vaccine innovation company, climbed 110.70% this week, according to data from S&P Global Intelligence. The jump was due to the company releasing data from a trial for its pneumonia vaccine VAX-24, which has a Fast Track designation from the Food and Drug Administration. On Monday, it followed up, saying VAX-24’s phase 1/2 trial of healthy adults 18-64 met its primary safety and tolerability targets and was similar in that way to Pfizer’s Prevnar 20 and could be a best-in-class pneumonia vaccine.

Read More

Add Comment

Click here to post a comment